title: Vitamin K antagonists in anticoagulant therapy of patients with cancer.
abstract: Venous thromboembolism (VTE) is a common complication of cancer. Prolonged use of low-molecular-weight heparin in cancer patients provides better VTE prophylaxis compared with vitamin K antagonists. Both therapeutic options have a similar safety profile. If patients on long-term oral anticoagulation are diagnosed with cancer, they should continue treatment with vitamin K antagonists.
authors.affiliation: Department of Cardiology and Internal Diseases, Międzyleski Hospital, Warszawa, Poland. tpasierski@mssw.pl
authors.forename: Tomasz
authors.initials: T
authors.lastname: Pasierski
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000627:therapeutic use*; D001777:Blood Coagulation / Q000187:drug effects; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000150:complications*; D013923:Thromboembolism / Q000188:drug therapy* / Q000209:etiology; D020246:Venous Thrombosis / Q000188:drug therapy* / Q000209:etiology; D014812:Vitamin K / Q000008:administration & dosage / Q000037:antagonists & inhibitors*
chemical_list: D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D014812:Vitamin K